Tumor Infiltrating Lymphocytes Market Report 2026

The tumor infiltrating lymphocytes market size has grown rapidly in recent years. It will grow from $12.05 billion in 2025 to $13.75 billion in 2026 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to increasing cancer prevalence, advancements in immunotherapy research, rising awareness of personalized medicine, early success of adoptive cell therapies, collaborations between research institutes and biotech companies.

The tumor infiltrating lymphocytes market size is expected to see rapid growth in the next few years. It will grow to $23.25 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to growing adoption of tumor infiltrating lymphocytes therapies, expansion of cGMP-compliant manufacturing facilities, integration of ai in cell therapy process optimization, rise in strategic partnerships between pharma and biotech, regulatory approvals for novel t-cell therapies. Major trends in the forecast period include personalized cell therapy development, ex vivo t-cell expansion techniques, immunotherapy combination approaches, tumor microenvironment modulation, advanced cell storage & cryopreservation.

The increasing number of cancer patients is expected to drive the growth of the tumor-infiltrating lymphocytes (TIL) market. Cancer occurs when some cells in the body grow uncontrollably and spread to other parts, leading to various health problems, including potentially fatal outcomes. Tumor-infiltrating lymphocytes are immune cells capable of detecting and destroying cancer cells. These lymphocytes are extracted from a patient's tumor, expanded in a laboratory, and then infused back into the patient to help the immune system fight cancer. For example, in August 2024, the Australian Institute of Health and Welfare projected that by 2034, Australia would have around 209,000 new cancer diagnoses, a significant increase from the 169,000 expected in 2024. This rise reflects both a growing population and increasing cancer rates. Cancer is also expected to account for about 3 out of every 10 deaths in the country in 2024. As a result, the growing number of cancer cases will drive the demand for TIL therapies.

Companies in the tumor-infiltrating lymphocyte market are increasingly adopting strategic partnerships to develop innovative treatments, including those involving gene editing. Strategic partnerships allow companies to leverage each other's strengths and resources to achieve mutual success. For instance, in February 2023, Moderna entered a partnership with Life Edit Therapeutics to accelerate the development of novel in vivo gene-editing therapies. This collaboration combines Moderna's mRNA technology with Life Edit's genome-editing platform to create more effective therapies for cancer and genetic disorders.

In May 2023, Phio Pharmaceuticals teamed up with AgonOx Inc. to advance TIL therapies for cancer treatment. This collaboration aims to combine Phio’s engineered TIL technology with AgonOx's expertise in immuno-oncology, potentially improving treatment options for patients with solid tumors. AgonOx focuses on developing innovative therapies for cancer patients, further enhancing the potential of TIL-based treatments.

Major companies operating in the tumor infiltrating lymphocytes market are Novartis AG, Pfizer Inc., Precision BioScience Inc., TCR2 Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Intellia Therapeutics Inc., MaxCyte Inc.

North America was the largest region in the tumor infiltrating lymphocytes market in 2025. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor infiltrating lymphocytes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the tumor infiltrating lymphocytes market by increasing the cost of importing specialized lab equipment, cell culture reagents, and bioreactors, particularly affecting North America and Europe, which rely on global suppliers. The high-cost segments such as ex vivo T-cell expansion and advanced cryopreservation are most affected. While tariffs may slow adoption in price-sensitive regions, they also encourage local manufacturing and innovation in TIL processing technologies, potentially strengthening domestic capabilities.

The tumor infiltrating lymphocytes market research report is one of a series of new reports that provides tumor infiltrating lymphocytes market statistics, including tumor infiltrating lymphocytes industry global market size, regional shares, competitors with a tumor infiltrating lymphocytes market share, detailed tumor infiltrating lymphocytes market segments, market trends and opportunities, and any further data you may need to thrive in the tumor infiltrating lymphocytes industry. This tumor infiltrating lymphocytes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tumor-infiltrating lymphocytes (TILs) are immune cells capable of identifying and eliminating cancer cells after they enter a tumor through the bloodstream. These cells are extracted from the patient's tumor, expanded in large quantities in a laboratory, and then reintroduced into the patient to help their immune system target and destroy cancer cells.

The key types of tumor-infiltrating lymphocytes include CD3, CD8, CD16, CD56, CD4, CD57, CD169, CD68, and FOXP3. CD3, also known as the T3 complex, is a multimeric protein complex that plays a crucial role in the activation of T-cells. Tumor-infiltrating lymphocytes consist of various components, including T-cells, B-cells, and natural killer (NK) cells. These immune cells are used in the treatment of various cancers, such as melanoma, cervical cancer, ovarian cancer, and more. The primary end-users of TIL therapy include hospitals, cancer research centers, and clinics.

The tumor infiltrating lymphocytes market consists of sales of autologous TILs (tumor infiltrating lymphocytes), allogeneic TILs, and engineered TILs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.